Probiotic Prophylaxis in Predicted Severe Acute Pancreatitis: A Randomised, Double-Blind, Placebo-Controlled Trial.

By T. Venkatesan. Nutrition in clinical practice, 2008

623 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/c76649623985c6eb0dfc4f82eefaffa104c3c243

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

In Surgery

Citations in the corpus

IAP/APA evidence-based guidelines for the management of acute pancreatitis. (2013, background): “Ecologic 641) did not prevent infectious complications but increased mortality [52].”
Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) (2009, background): “With regard to safety issues of probiotic provision to critically ill patients, cases of fungemia in ICU patients associated with the use of Saccaromyces boulardii, as well as worsened clinical outcomes in severe pancreatitis patients, have been reported.(206,207) Although no other infection or bact”
Intestinal permeability – a new target for disease prevention and therapy (2014, result): “Whereas a few initial studies suggested beneficial effects by treatment with synbiotics [252,253], one trial reported increased mortality in the verum group [254].”
Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). (2009, background): “With regard to safety issues of probiotic provision to critically ill patients, cases of fungemia in ICU patients associated with the use of Saccaromyces boulardii, as well as worsened clinical outcomes in severe pancreatitis patients, have been reported.(206,207) Although no other infection or bact”
Safety assessment of probiotics for human use (2010, result): “However, the question of safety of probiotics for critically ill patients is paramount, especially in light of observations of higher mortality in a probiotic intervention group than a control group in a study using critically ill patients with acute pancreatitis.(6) In this study, 296 predicted sev”
Genes and Molecules of Lactobacilli Supporting Probiotic Action (2008, background): “However, in rare cases, reports of infections presumably caused by probiotic lactobacilli in immunocompromised patients or patients with severe underlying disease have been published (21, 146).”
The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept) (2011, background): “However, the administration of viable bacterial cells to individuals with weaker immune systems, enhanced inflammatory responses and/or compromised mucosal barrier functions could turn ‘generally recognised as safe’ harmless probiotic bacteria into detrimental microorganisms (Besselink et al. 2008).”
Microorganisms with Claimed Probiotic Properties: An Overview of Recent Literature (2014, result): “the use of probiotics in patients suffering severe acute pancreatitis where a significantly higher mortality was observed for the probiotics group than for the placebo group [105], although these results were unexpected in the light of the results of animal studies [106].”
Can Animal Models of Disease Reliably Inform Human Studies? (2010, neutral): “infarction [4–7].”
Risk and safety of probiotics. (2015, background): “One clinical trial [72] caused significant concern about probiotic safety.”